Nowadays mainly intranasal insulin treatment is the best published compound regarding AD, as it improves memory and learning in AD models (Reger et al., 2008; Farzampour et al., 2016; Mao et al., 2016; Guo et al., 2017), it lowers Aβ in diabetes models (Subramanian and John, 2012), it modulates verbal memory (Reger et al., 2008) or it prevents tau phosphorylation in 3xTg mice (Chen et al., 2014) and type II diabetes (Yang et al., 2013). The gene discussed is MAPT; the disease is Alzheimer disease.